Valeriano Leite

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/229306/publications.pdf

Version: 2024-02-01

81 papers	3,210 citations	172457 29 h-index	155660 55 g-index
82 all docs	82 docs citations	82 times ranked	3506 citing authors

#	Article	IF	Citations
1	Letter to Editor response. Thyroid, 2022, , .	4.5	0
2	Parathyroid carcinoma: Single centre experience. Clinical Endocrinology, 2022, , .	2.4	5
3	Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma. Clinical Endocrinology, 2022, 97, 814-821.	2.4	2
4	Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma. Journal of Endocrinological Investigation, 2021, 44, 1837-1846.	3.3	7
5	A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer. Endocrine, 2021, 73, 588-597.	2.3	3
6	Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer. Thyroid, 2021, 31, 1514-1522.	4.5	3
7	Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer. Thyroid, 2021, 31, 1366-1375.	4.5	9
8	Mediastinal Thyroid Carcinoma and Gravesâ€™ Disease: A Rare Presentation. Case Reports in Endocrinology, 2021, 2021, 1-4.	0.4	0
9	Chromogranin A and NSE in cystic pancreatic neuroendocrine tumors. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101601.	1.5	3
10	Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines. Nutrition and Cancer, 2020, 72, 352-363.	2.0	13
11	The role of EIF1AX in thyroid cancer tumourigenesis and progression. Journal of Endocrinological Investigation, 2019, 42, 313-318.	3.3	18
12	Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology. Endocrine, 2019, 66, 288-300.	2.3	2
13	Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options. Cancers, 2019, 11, 1188.	3.7	25
14	SDHx-related pheochromocytoma/paraganglioma â€“ genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. Endocrine, 2019, 65, 408-415.	2.3	5
15	The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. Journal of Endocrinological Investigation, 2019, 42, 527-540.	3.3	17
16	Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience. European Thyroid Journal, 2019, 8, 96-101.	2.4	16
17	Tc-99m sestamibi scintigraphy and primary hyperparathyroidism: uptake beyond parathyroid glands. BMJ Case Reports, 2018, 2018, bcr-2018-225232.	0.5	2
18	Poorly Differentiated Thyroid Carcinoma Patients with Detectable Thyroglobulin Levels after Initial Treatment Show an Increase in Mortality and Disease Recurrence. European Thyroid Journal, 2018, 7, 313-318.	2.4	5

#	Article	IF	Citations
19	Ultrasound requested by general practitioners or for symptoms unrelated to the thyroid gland may explain higher prevalence of thyroid nodules in females. Clinical Imaging, 2018, 50, 289-293.	1.5	17
20	Homozygous Calcium-Sensing Receptor Polymorphism R544Q Presents as Hypocalcemic Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2879-2888.	3.6	18
21	The Importance of the 2015 American Thyroid Association Guidelines for Adults with Thyroid Nodules and Differentiated Thyroid Cancer in Minimising Overdiagnosis and Overtreatment of Thyroid Carcinoma. European Endocrinology, 2018, 14, 13.	1.5	1
22	Lymph Node Metastases in Papillary and Medullary Thyroid Carcinoma Are Independent of Intratumoral Lymphatic Vessel Density. European Thyroid Journal, 2017, 6, 57-64.	2.4	14
23	Identification of somatic <scp>TERT</scp> promoter mutations in familial nonmedullary thyroid carcinomas. Clinical Endocrinology, 2017, 87, 394-399.	2.4	23
24	TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1898-1907.	3.6	113
25	Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?. Thyroid, 2017, 27, 1068-1076.	4.5	42
26	External ear invasion from an anaplastic thyroid cancer. Endocrine, 2017, 55, 320-321.	2.3	0
27	Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. Oncology Letters, 2016, 11, 3870-3874.	1.8	17
28	A case of thyroid fibromatosis, a rare lesion of this gland. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.5	4
29	Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up. Oncology Letters, 2015, 9, 1281-1286.	1.8	1
30	Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma. Endocrine, 2015, 49, 366-372.	2.3	7
31	RAS proto-oncogene in medullary thyroid carcinoma. Endocrine-Related Cancer, 2015, 22, R235-R252.	3.1	83
32	Review of clinical and pathological features of 93 cases of well-differentiated thyroid carcinoma in pediatric age at the Lisbon Centre of the Portuguese Institute of Oncology between 1964 and 2006. International Journal of Pediatric Otorhinolaryngology, 2015, 79, 1324-1329.	1.0	9
33	Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Endocrine, 2015, 49, 204-214.	2.3	61
34	Aggressive pituitary lesion with a remarkably high Ki-67. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 656-660.	1.3	8
35	Retrospective Analysis of 255 Papillary Thyroid Carcinomas â‰¤2 cm: Clinicohistological Features and Prognostic Factors. European Thyroid Journal, 2014, 3, 258-263.	2.4	11
36	Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. European Journal of Endocrinology, 2014, 170, 321-327.	3.7	40

#	Article	IF	Citations
37	Anaplastic Carcinoma and Toxic Multinodular Goiter: An Unusual Presentation. European Thyroid Journal, 2014, 3, 278-82.	2.4	5
38	Cell Cycle Deregulation andTP53andRASMutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E497-E507.	3.6	79
39	TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E754-E765.	3.6	451
40	<scp>FOXE1</scp> polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clinical Endocrinology, 2012, 77, 926-933.	2.4	57
41	2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer. European Thyroid Journal, 2012, 1, 216-231.	2.4	88
42	<scp>S</scp>â€phase fraction and ploidy as predictive markers in primary disease and recurrence of papillary thyroid carcinoma. Clinical Endocrinology, 2012, 77, 302-309.	2.4	4
43	High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E863-E868.	3.6	204
44	Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses. Endocrine Pathology, 2011, 22, 44-52.	9.0	22
45	Clinical and genetic characterization of Portuguese patients with pseudohypoparathyroidism type Ib. Endocrine, 2010, 37, 408-414.	2.3	17
46	Differential Methylation as a Cause of Allele Dropout at the ImprintedGNASLocus. Genetic Testing and Molecular Biomarkers, 2010, 14, 455-460.	0.7	4
47	Underexpression of PPARÎ³ is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. Oncology Reports, 2009, 22, 907-13.	2.6	5
48	Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. British Journal of Cancer, 2009, 100, 1777-1783.	6.4	150
49	Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. British Journal of Cancer, 2009, 101, 1782-1791.	6.4	76
50	Clinical implications of molecular markers in follicular cell-derived thyroid cancer. Expert Review of Molecular Diagnostics, 2009, 9, 679-694.	3.1	4
51	Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocrine-Related Cancer, 2008, 15, 207-215.	3.1	52
52	Mapping a New Familial Thyroid Epithelial Neoplasia Susceptibility Locus to Chromosome 8p23.1-p22 by High-Density Single-Nucleotide Polymorphism Genome-Wide Linkage Analysis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4426-4430.	3.6	68
53	Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma. Oncology Reports, 2008, 20, 913-9.	2.6	11
54	PAX8PPARÎ³ Stimulates Cell Viability and Modulates Expression of Thyroid-Specific Genes in a Human Thyroid Cell Line. Thyroid, 2007, 17, 497-509.	4.5	20

#	Article	IF	Citations
55	Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. British Journal of Cancer, 2007, 96, 1237-1245.	6.4	42
56	Aneuploidy and RAS mutations are mutually exclusive events in the development of wellâ€differentiated thyroid follicular tumours. Clinical Endocrinology, 2007, 67, 706-711.	2.4	17
57	Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncology Reports, 2007, 18, 917-26.	2.6	36
58	Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. Clinical Endocrinology, 2006, 64, 179-183.	2.4	9
59	Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clinical Endocrinology, 2006, 64, 299-306.	2.4	105
60	PROP1 gene analysis in Portuguese patients with combined pituitary hormone deficiency. Clinical Endocrinology, 2006, 65, 479-485.	2.4	39
61	Authors' response: Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. Clinical Endocrinology, 2006, 65, 549-549.	2.4	0
62	Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. Journal of Endocrinology, 2006, 191, 229-238.	2.6	56
63	Metastatic Follicular Carcinoma Associated With Hyperthyroidism. Clinical Nuclear Medicine, 2005, 30, 79-82.	1.3	15
64	Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. European Journal of Endocrinology, 2005, 153, 701-709.	3.7	68
65	Hyperparathyroidism-Jaw Tumor Syndrome in Roma Families from Portugal Is Due to a Founder Mutation of the HRPT2 Gene. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1747-1752.	3.6	65
66	Underexpression of peroxisome proliferator-activated receptor (PPAR)Î³ in PAX8/PPARÎ³-negative thyroid tumours. British Journal of Cancer, 2004, 91, 732-738.	6.4	64
67	Preoperative Diagnosis of Suspicious Parathyroid Adenomas by RT-PCR Using mRNA Extracted from Leftover Cells in a Needle Used for Ultrasonically Guided Fine Needle Aspiration Cytology. Acta Cytologica, 2003, 47, 5-12.	1.3	10
68	Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. European Journal of Endocrinology, 2002, 146, 27-33.	3.7	42
69	Expression of PAX8-PPARÎ³1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3947-3952.	3.6	285
70	Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline deletions. Clinical Endocrinology, 2002, 56, 465-473.	2.4	51
71	The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 213-222.	0.5	65
72	Medullary Carcinomas of the Thyroid: A Monoclonal Origin. Thyroid, 2001, 11, 1109-1113.	4.5	3

#	Article	IF	Citations
73	Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. Journal of Endocrinological Investigation, 1999, 22, 203-208.	3.3	68
74	Spontaneously occurring anti-PTH autoantibodies must be considered in the differential diagnosis of patients with elevated serum PTH levels1. Journal of Endocrinological Investigation, 1999, 22, 829-834.	3.3	8
75	Regulation of Galanin by Dexamethasone in the Rat Anterior Pituitary and the Uterus. Neuroendocrinology, 1996, 64, 20-24.	2.5	7
76	A possible role for D8/PSF-A-like sequences in lactotroph versus somatotroph expression of the human prolactin gene. Journal of Endocrinology, 1996, 149, 473-483.	2.6	3
77	Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2342-2346.	3.6	89
78	Bromocriptine Inhibits Galanin Gene Expression in the Rat Pituitary Gland. Molecular and Cellular Neurosciences, 1993, 4, 418-423.	2.2	1
79	Estrogen Regulation and Localization of Galanin Gene Expression in the Rat Uterus1. Biology of Reproduction, 1993, 49, 1245-1250.	2.7	16
80	Characterization of big, big prolactin in patients with hyperprolactinaemia. Clinical Endocrinology, 1992, 37, 365-372.	2.4	122
81	Study of the Source(s) of Hyperandrogenism in Women with Idiopathic Hirsutism. Hormone and Metabolic Research, 1990, 22, 499-503.	1.5	3